Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.37 |
| ▸ | BCL2 | P10415 | 3/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | EDNRB | P24530 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103994 | 0.86 | PTGES (0.56) | PTGESKMT2AMCL1BCL2MDM2 | |
| SCHEMBL4092445 | 0.85 | PTGES (0.46) | PTGESKMT2AMCL1BCL2MDM2 | |
| SCHEMBL4105667 | 0.83 | PTGES (0.48) | PTGESKMT2AMCL1BCL2MDM2 | |
| SCHEMBL4098949 | 0.72 | PTGES (0.41) | PTGESKMT2AMCL1BCL2MDM2 | |
| SCHEMBL4924661 | 0.70 | PTGES (0.67) | PTGESKMT2AMCL1BCL2MDM2 | |
| SCHEMBL3574806 | 0.70 | PTGES (0.85) | PTGESKMT2AMCL1BCL2MDM2 | |
| SCHEMBL3574822 | 0.70 | PTGES (0.71) | PTGESKMT2AMCL1BCL2MDM2 | |
| SCHEMBL5319595 | 0.70 | PTGES (0.67) | PTGESKMT2AMCL1BCL2MDM2 | |
| SCHEMBL4097942 | 0.69 | PTGES (0.57) | PTGESKMT2AMCL1BCL2MDM2 | |
| SCHEMBL4099400 | 0.68 | ALDH1A1 (0.39) | PTGESALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2009-03-12 | — | — | US | disclosed |
| EP-1844051-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006077412-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | NPY5R, TH, PTGES | PTGES 3/4885KMT2A 4308/4885MCL1 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.